PMID- 36539856
OWN - NLM
STAT- MEDLINE
DCOM- 20221222
LR  - 20230113
IS  - 2044-5040 (Electronic)
IS  - 2044-5040 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Dec 21
TI  - The prevalence of low muscle mass associated with obesity in the USA.
PG  - 26
LID - 10.1186/s13395-022-00309-5 [doi]
LID - 26
AB  - BACKGROUND: Sarcopenia is defined as age-related low muscle mass and function, 
      and can also describe the loss of muscle mass in certain medical conditions, such 
      as sarcopenic obesity. Sarcopenic obesity describes loss of muscle and function 
      in obese individuals; however, as sarcopenia is an age-related condition and 
      obesity can occur in any age group, a more accurate term is obesity with low lean 
      muscle mass (OLLMM). Given limited data on OLLMM (particularly in those aged < 65 
      years), the purpose of this study was to estimate the prevalence of OLLMM in 
      adults aged >/= 20 years in the USA. METHODS: Data from the National Health and 
      Nutrition Examination Survey (NHANES) 2017-2018 and 1999-2006 were used. OLLMM 
      was defined as an appendicular lean mass, adjusted for body mass index (BMI), 
      cut-off point < 0.789 for males and < 0.512 for females, measured by dual-energy 
      X-ray absorptiometry (DXA). DXA was only measured in individuals 20-59 years old 
      in NHANES 2017-2018; we therefore utilized logistic regression models to predict 
      OLLMM from NHANES 1999-2006 for those aged >/= 60 years. The prevalence of OLLMM 
      was estimated overall, and by sex, age, race/ethnicity, and clinical subgroup 
      (high BMI, prediabetes, type 2 diabetes mellitus [T2DM], non-alcoholic fatty 
      liver disease [NAFLD] with fibrosis, or post-bariatric surgery). Prevalence 
      estimates were extrapolated to the USA population using NHANES sampling weights. 
      RESULTS: We estimated that, during 2017-2018, 28.7 million or 15.9% of the USA 
      population had OLLMM. The prevalence of OLLMM was greater in older individuals 
      (8.1%, aged 20-59 years vs 28.3%, aged >/= 60 years), highest (66.6%) in 
      Mexican-American females aged >/= 60 years, and lowest (2.6%) in non-Hispanic Black 
      males aged 20-59 years. There was a higher prevalence of OLLMM in adults with 
      prediabetes (19.7%), T2DM (34.5%), NAFLD with fibrosis (25.4%), or post-bariatric 
      surgery (21.8%), compared with those without each condition. CONCLUSIONS: 
      Overall, the burden of OLLMM in the USA is substantial, affecting almost 30 
      million adults. The prevalence of OLLMM increased with age, and among those with 
      prediabetes, T2DM, NAFLD with fibrosis, or post-bariatric surgery. A unified 
      definition of OLLMM will aid diagnosis and treatment strategies.
CI  - (c) 2022. The Author(s).
FAU - Murdock, Dana J
AU  - Murdock DJ
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Wu, Ning
AU  - Wu N
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Grimsby, Joseph S
AU  - Grimsby JS
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Calle, Roberto A
AU  - Calle RA
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Donahue, Stephen
AU  - Donahue S
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Glass, David J
AU  - Glass DJ
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Sleeman, Mark W
AU  - Sleeman MW
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA.
FAU - Sanchez, Robert J
AU  - Sanchez RJ
AD  - Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 
      10591-6707, USA. robert.sanchez@regeneron.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221221
PL  - England
TA  - Skelet Muscle
JT  - Skeletal muscle
JID - 101561193
SB  - IM
MH  - Male
MH  - Adult
MH  - Female
MH  - Humans
MH  - Aged
MH  - Young Adult
MH  - Middle Aged
MH  - *Sarcopenia/epidemiology
MH  - Nutrition Surveys
MH  - *Non-alcoholic Fatty Liver Disease/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Prevalence
MH  - *Prediabetic State/complications
MH  - Obesity/complications/epidemiology
MH  - Fibrosis
MH  - Muscles
MH  - Body Composition
PMC - PMC9769063
OTO - NOTNLM
OT  - Atrophy
OT  - Body mass index
OT  - Muscle loss
OT  - Prevalence
OT  - Sarcopenia
OT  - Sarcopenic obesity
COIS- All authors are employees and stockholders of Regeneron Pharmaceuticals, Inc.
EDAT- 2022/12/21 06:00
MHDA- 2022/12/23 06:00
PMCR- 2022/12/21
CRDT- 2022/12/20 23:58
PHST- 2022/06/15 00:00 [received]
PHST- 2022/11/22 00:00 [accepted]
PHST- 2022/12/20 23:58 [entrez]
PHST- 2022/12/21 06:00 [pubmed]
PHST- 2022/12/23 06:00 [medline]
PHST- 2022/12/21 00:00 [pmc-release]
AID - 10.1186/s13395-022-00309-5 [pii]
AID - 309 [pii]
AID - 10.1186/s13395-022-00309-5 [doi]
PST - epublish
SO  - Skelet Muscle. 2022 Dec 21;12(1):26. doi: 10.1186/s13395-022-00309-5.